LEVOCARNITINE SF Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Levocarnitine Sf patents expire, and when can generic versions of Levocarnitine Sf launch?
Levocarnitine Sf is a drug marketed by Novitium Pharma and is included in one NDA.
The generic ingredient in LEVOCARNITINE SF is levocarnitine. There are four drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the levocarnitine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Levocarnitine Sf
A generic version of LEVOCARNITINE SF was approved as levocarnitine by HIKMA on March 29th, 2001.
Summary for LEVOCARNITINE SF
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 23 |
Formulation / Manufacturing: | see details |
DailyMed Link: | LEVOCARNITINE SF at DailyMed |

Recent Clinical Trials for LEVOCARNITINE SF
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Children's Oncology Group | Phase 3 |
University of California, Irvine | Early Phase 1 |
Children's Hospital of Orange County | Early Phase 1 |
Pharmacology for LEVOCARNITINE SF
Drug Class | Carnitine Analog |
Anatomical Therapeutic Chemical (ATC) Classes for LEVOCARNITINE SF
US Patents and Regulatory Information for LEVOCARNITINE SF
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novitium Pharma | LEVOCARNITINE SF | levocarnitine | SOLUTION;ORAL | 211676-002 | Aug 14, 2019 | AA | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |